Pantherna Therapeutics, a Hennigsdorf, Germany-based life science startup, secured €3.5m in seed financing.
Backers included High-Tech Gründerfonds (HTGF), European Business Angel Prof. Detlev Riesner as well as the European Investment Fund and the State of Brandenburg.
The funds will be used to advance R&D activities and hire additional scientific staff.
Led by Dr. Klaus Giese, CEO, and Jörg Kaufmann, CSO, Gerrit Maass, CFO, and Oliver Keil, CTO, Pantherna Therapeutics is a biopharmaceutical Company developing therapeutics for vascular diseases based on a technology platform featuring advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs to treat Acute Respiratory Distress Syndrome (ARDS), a severe lung disease.
The platform is also unfolding into further applications.